Clinical Trial Update: Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain [Phase 3]

View source ↗

Summary

Phase 3 trial update for subcutaneous MOA-728 in opioid-induced constipation associated with chronic non-malignant pain; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• MOA-728

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Constipation | Phase 3 | Status: COMPLETED | Results posted: 2010-05-11